Food and Drug Administration (FDA): Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed Were Recently Added

Front Cover
DIANE Publishing, 2011 - 63 pages
0 Reviews
In early 2008, the FDA responded to a crisis involving the contamination of heparin, a medication used to prevent and treat blood clots, when the agency received multiple reports of adverse events involving severe allergic reactions. The crisis took place from January 2008 through May 2008, during which time FDA took several actions in its response to the crisis. This report reviewed FDA's management of the heparin crisis. This report examines: (1) how FDA prevented additional contaminated heparin from reaching U.S. consumers; (2) how FDA coordinated its response to the contaminated heparin crisis; and (3) FDA's monitoring and analysis of adverse events associated with heparin. Charts and tables. This is a print on demand report.

What people are saying - Write a review

We haven't found any reviews in the usual places.

Common terms and phrases

Bibliographic information